Dynavax Announces Successful Proxy Contest

New York – June 11, 2025 – Cooley advised Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, on its successful proxy contest against Deep Track Capital, which sought to replace four directors on Dynavax’s nine-member board. Based on a preliminary vote assessment, stockholders elected all four of Dynavax’s nominees at its annual stockholder meeting.

Lawyers Bill Roegge, Steve Przesmicki, Barbara Borden, Julia Kim, Patrick Reed and Matt Choy led the Cooley team advising Dynavax, with support from Sarah Lightdale and Brian Golger on litigation matters.

This represents the largest proxy contest of 2025 to date at a biotechnology company and the largest proxy contest at a US-listed vaccine company on record. Cooley also advised Dynavax on its adoption of a limited-duration stockholder rights plan.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.